Ruxolitinib Cream for AD Is in Regulatory Home Stretch Ruxolitinib Cream for AD Is in Regulatory Home Stretch

Ruxolitinib cream, now under priority review by the FDA for the treatment of AD down to age 12 years, demonstrated a dual mechanism of action in two pivotal phase 3 trials: antipruritic and anti-inflammatory.Medscape Medical News
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Dermatology News Source Type: news